Two Common Antiseizure Medications Do Not Harm Child Neurodevelopment
By Lori Solomon HealthDay Reporter
TUESDAY, Dec. 3, 2024 -- Fetal exposure to two common antiseizure medications (ASMs) does not seem to negatively impact children's neurological development at age 6 years, according to a study published online Nov. 25 in JAMA Neurology.
Kimford J. Meador, M.D., from the Stanford University School of Medicine in Palo Alto, California, and colleagues compared the outcomes of 6-year-old children of women with epilepsy (WWE) versus those of healthy women to assess the association of outcomes to third-trimester ASM exposures. The analysis included 298 children of WWE and 89 children of healthy women.
The researchers found that the two groups of children did not differ on the Verbal Index Score, but there was variance based on the amount of ASM exposure. Lamotrigine showed positive exposure-dependent associations, while levetiracetam showed negative exposure-dependent associations. Across ASMs, exposure-dependent outcomes differed. Three-quarters of WWE (78 percent) were taking lamotrigine or levetiracetam alone or in combination, so assessment of other ASMs was limited. There were positive associations for folate supplementation during the first 12 weeks of pregnancy with cognition and behavior, with no signal for risks at higher folate doses.
"Because all ASMs are potential teratogens, and teratogens act in an exposure-dependent manner, the clinical challenge is to provide a dose sufficiently high to protect the mother and fetus from seizures but at the lowest effective concentration to minimize fetal risks," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
All-Cause Mortality Higher With Sleep Deprivation in Seniors With Epilepsy
MONDAY, May 19, 2025 -- Older adults with sleep deprivation and epilepsy have an elevated risk for all-cause mortality, according to a study published online April 23 in...
New Definition of Epilepsy Improves Diagnosis, Treatment
TUESDAY, April 15, 2025 -- The new International League Against Epilepsy (ILAE) definition of epilepsy results in a higher frequency of epilepsy diagnosis and treatment, according...
Medial Temporal Lobectomy Aids Seizure Outcomes in Epilepsy
MONDAY, April 14, 2025 -- Medial temporal lobectomy is effective in improving seizure outcomes among patients with drug-resistant temporal lobe epilepsy, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.